Automated insulin delivery (AID) systems have proven safe and effective in improving glycemic outcomes in individuals with type 1 diabetes. Clinical evaluation of this technology has progressed to large randomized, controlled outpatient studies and recent commercial approval of AID systems for children and adults. However, several challenges remain in improving these systems for different subpopulations (e.g. young children, athletes, pregnant women, seniors, and those with hypoglycemia unawareness). In this review, we highlight the requirements and challenges in AID design for selected subpopulations and discuss current advances from recent clinical studies.

Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations

Aiello, Eleonora M.;
2021-01-01

Abstract

Automated insulin delivery (AID) systems have proven safe and effective in improving glycemic outcomes in individuals with type 1 diabetes. Clinical evaluation of this technology has progressed to large randomized, controlled outpatient studies and recent commercial approval of AID systems for children and adults. However, several challenges remain in improving these systems for different subpopulations (e.g. young children, athletes, pregnant women, seniors, and those with hypoglycemia unawareness). In this review, we highlight the requirements and challenges in AID design for selected subpopulations and discuss current advances from recent clinical studies.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11571/1507217
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 20
social impact